Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Moli-1901 granted orphan drug status in Europe

Jan. 13, 2003

Promising effects of AEOL-10113 in hyperoxic preterm fetal baboons

Jan. 13, 2003

Merck Frosst develops novel PDE4 inhibitors

Jan. 13, 2003

Patient treatment under way in phase II trial of DCF-987 for cystic fibrosis

Jan. 10, 2003

Merck Frosst scientists discover novel prostaglandin D2 receptor antagonists

Jan. 9, 2003

FDA approves Singulair for seasonal allergic rhinitis

Jan. 9, 2003

Thiazolidinone CFTR channel inhibitor identified at UCSF

Jan. 8, 2003

New JAK3 inhibitors identified at AstraZeneca

Jan. 7, 2003

MoliChem reacquires rights to Moli-1901

Jan. 7, 2003

Foradil Certihaler filed for approval in the U.S.

Jan. 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.